Stabilization of disease as a useful predictor of survival following second-line chemotherapy in small cell lung cancer and ovarian cancer patients

Int J Oncol. 1999 Dec;15(6):1233-8. doi: 10.3892/ijo.15.6.1233.

Abstract

To assess the value of disease stabilization (SD) as a predictor of survival following chemotherapy, data were analyzed from multicenter clinical trials in small cell lung cancer (SCLC) and ovarian cancer (OC) patients receiving various second-line chemotherapy regimens. In both patient populations, SD (lasting >8 weeks) and partial responses (PR) were associated with a survival benefit versus progressive disease (PD); interestingly, the survival benefit was similar between the two groups (PR and SD). These results suggest that, at least in these populations, SD may represent a potential benefit of chemotherapy and therefore the distinction between SD and PR may not be useful.

Publication types

  • Comparative Study

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Antineoplastic Agents / therapeutic use
  • Carcinoma, Small Cell / drug therapy
  • Carcinoma, Small Cell / mortality*
  • Clinical Trials as Topic
  • Clinical Trials, Phase II as Topic
  • Clinical Trials, Phase III as Topic
  • Cyclophosphamide / therapeutic use
  • Doxorubicin / therapeutic use
  • Female
  • Follow-Up Studies
  • Humans
  • Lung Neoplasms / drug therapy
  • Lung Neoplasms / mortality*
  • Male
  • Middle Aged
  • Multicenter Studies as Topic
  • Ovarian Neoplasms / drug therapy
  • Ovarian Neoplasms / mortality*
  • Paclitaxel / therapeutic use
  • Prognosis
  • Salvage Therapy
  • Survival Analysis
  • Survival Rate
  • Time Factors
  • Topotecan / therapeutic use
  • Treatment Outcome

Substances

  • Antineoplastic Agents
  • Topotecan
  • Doxorubicin
  • Cyclophosphamide
  • Paclitaxel